Do Statins “REPRIEVE” People Living with HIV from CV Events?

As people living with HIV age, the risk of cardiovascular disease becomes the greatest threat to their health and quality of life. Not only does inflammation from HIV infection contribute to atherosclerotic cardiovascular disease (ASCVD), but dyslipidemia from the antivirals commonly used to treat HIV further enhances that risk. But does statin therapy reduce ASCVD risk in patients living with HIV?  That's the question that the REPRIEVE study attempted to answer.

Guest Authors:  Laura Lerner, PharmD and Joseph Nardolillo, PharmD, BCACP

Music by Guest Talk